# Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

> **NCT01136252** · PHASE2 · COMPLETED · sponsor: **Hospital Universitari Vall d'Hebron Research Institute** · enrollment: 5 (actual)

## Conditions studied

- Age-Related Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT01136252
- **Lead sponsor:** Hospital Universitari Vall d'Hebron Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-09
- **Final completion:** 2011-10
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2012-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01136252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01136252, "Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01136252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*